Literature DB >> 28463344

Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin.

Victoria Hendrick1, Robert Dasher, Michael Gitlin, Mehrban Parsi.   

Abstract

BACKGROUND: Patients taking antipsychotic medications are at high risk for weight gain, which in turn leads to poor health outcomes, nonadherence with treatment, and low self-esteem.
METHODS: We reviewed published studies of pharmacologic interventions aimed at minimizing antipsychotic-induced weight gain. Treatments initiated prior to onset of weight gain were compared with those that started once weight gain already had occurred.
RESULTS: Although data are limited, adjunctive medications for weight management appear to be more effective when initiated at or near the time when patients are first exposed to antipsychotic medications. Interventions initiated later in the course of treatment-typically after weight gain already has occurred-rarely help patients return to their pretreatment weight. The most commonly used adjunctive intervention has been metformin.
CONCLUSIONS: Certain patients benefit from initiating metformin early in their exposure to second-generation antipsychotic agents. In particular, young, healthy patients beginning olanzapine or clozapine probably will experience less weight gain if they concomitantly initiate metformin.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28463344

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  6 in total

Review 1.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 2.  Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.

Authors:  Pierre Ellul; Richard Delorme; Samuele Cortese
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

3.  Increasing Psychiatrists' Role in Addressing the Cardiovascular Health of Patients With Severe Mental Illness.

Authors:  Martha Ward
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 4.  Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.

Authors:  Esther Letícia Amorim Ribeiro; Tácio de Mendonça Lima; Marcio Eduardo Bergamini Vieira; Sílvia Storpirtis; Patricia Melo Aguiar
Journal:  Eur J Clin Pharmacol       Date:  2018-06-15       Impact factor: 2.953

5.  Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.

Authors:  Ching-Ping Yang; Ya-Yu Wang; Shih-Yi Lin; Yi-Jheng Hong; Keng-Ying Liao; Sheng-Kuo Hsieh; Ping-Ho Pan; Chun-Jung Chen; Wen-Ying Chen
Journal:  Int J Mol Sci       Date:  2019-02-01       Impact factor: 5.923

Review 6.  The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Authors:  Mark R Libowitz; Erika L Nurmi
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.